Evaluation of Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia (ALL) Receiving Hyper-CVAD Treatment in Seyyed Al-Shohada Hospital: Isfahan, 2014-2019

Alireza Sadeghi; Reyhane Gardashti; Farzaneh Ashrafi; Valiollah Mehrzad

doi:10.18502/ijhoscr.v18i1.14743

Alireza Sadeghi Department of Hematology and Oncology, Isfahan University of Medical Sciences, Isfahan, Iran
Reyhane Gardashti Isfahan University of Medical Sciences, Isfahan, Iran
Farzaneh Ashrafi Department of Hematology and Oncology, Isfahan University of Medical Sciences, Isfahan, Iran
Valiollah Mehrzad Department of Hematology and Oncology, Isfahan University of Medical Sciences, Isfahan, Iran

DOI: https://doi.org/10.18502/ijhoscr.v18i1.14743

Keywords: CNS relapse; Acute lymphoblastic leukemia; Hyper CVAD treatment; One-year survival

Abstract

Background: Recurrence of ALL in the central nervous system, CNS Relapse, is known as a poor prognostic factor. Few studies have been performed on the CNS Relapse in adults with ALL. This study aimed to evaluate the recurrence of acute lymphoblastic leukemia in the central nervous system, CNS relapse, in adults with ALL.

Materials and Methods: Seventy newly diagnosed patients with acute lymphoblastic leukemia aged 15 years and older referred to Seyyed Al-Shohada Hospital in Isfahan between 2014 and 2019 were included in this study. All patients treated with the Hyper-CVAD regimen underwent prophylaxis for the central nervous system based on the risk of CNS relapse. All study participants with CNS relapse underwent intrathecal chemotherapy.

Results: The median age of patients was 34 years. Four patients (5.7%) had primary central nervous system involvement. Out of 70 patients receiving the Hyper-CVAD regimen, 59 (84.2%) achieved complete remission. Of the 59 patients achieving CR, ten (16.94%) developed CNS relapse.

The median duration of CR before CNS relapse was 21 weeks. Out of 10 patients with CNS relapse, seven (70%) achieved complete remission. Of seven patients achieving CR in the central nervous system, one had a second recurrence in the central nervous system, but finally achieved CNS complete remission. The median survival of patients after CNS relapse was four months. The results also showed that out of 10 patients with CNS relapse, four (40%) survived one year.

Conclusion: This study shows that the prognosis of CNS relapse in adults with ALL has not improved much. Limited studies have been conducted on the recurrence of the central nervous system in adults with acute lymphoblastic leukemia. Therefore, further studies on CNS relapse after complete remission of ALL are required to clarify more details.